Several studies presented at ADA 2016 discussed going beyond basal insulin treatments for patients with type 2 diabetes.
Several studies presented at the 2016 American Diabetes Association annual meeting dealt with going beyond basal insulin treatments for type 2 diabetes mellitus (DM) patients. Here are the highlights from four abstracts on treatment intensification options.
Beyond Basal Insulin in Type 2 Diabetes. from ADA Scientific Sessions
Insulin Degludec/Liraglutide vs. Insulin Glargine. Abstract link.
Patients with T2DM treated with insulin degludec/liraglutide have a greater chance of reaching glycemic targets.
Insulin degludec/liraglutide led to better glycemic control.